Terminated × Leukemia, Lymphocytic, Chronic, B-Cell × Clear all A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
Phase 1 Terminated
84 enrolled
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
Phase 2 Terminated
5 enrolled 11 charts
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Phase 1 Terminated
69 enrolled 47 charts
topMIND
Phase 1/2 Terminated
54 enrolled 23 charts
TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Phase 2 Terminated
12 enrolled 10 charts
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Phase 2 Terminated
30 enrolled
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
Phase 1/2 Terminated
3 enrolled
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Phase 1 Terminated
84 enrolled
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
Phase 1 Terminated
25 enrolled
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
Phase 2 Terminated
4 enrolled 7 charts
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Phase 1 Terminated
1 enrolled
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
CORONADO CLL
Phase 1/2 Terminated
5 enrolled 13 charts
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
Phase 2 Terminated
2 enrolled 6 charts
VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib
Phase 1 Terminated
39 enrolled 30 charts
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Phase 2 Terminated
4 enrolled 8 charts
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Phase 1 Terminated
10 enrolled
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma
Phase 2 Terminated
30 enrolled
A Study Of The Selective PKC-β Inhibitor MS- 553
Phase 1/2 Terminated
60 enrolled 20 charts
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Phase 2 Terminated
9 enrolled 11 charts
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
Phase 1 Terminated
272 enrolled
R/R
Phase 1/2 Terminated
1 enrolled 4 charts
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Phase 1 Terminated
36 enrolled
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
Phase 1 Terminated
16 enrolled
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Phase 2 Terminated
55 enrolled
UNITY-CLL
Phase 3 Terminated
603 enrolled 17 charts
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Phase 1/2 Terminated
46 enrolled 35 charts
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Phase 1 Terminated
60 enrolled
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Terminated
3 enrolled 11 charts
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
Phase 1 Terminated
4 enrolled
Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Terminated
350 enrolled
The clonoSEQ® Watch Registry
Terminated
465 enrolled
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
Phase 1/2 Terminated
20 enrolled
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Terminated
3 enrolled
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Phase 1 Terminated
172 enrolled
A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL
Phase 1/2 Terminated
13 enrolled
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
Phase 1/2 Terminated
8 enrolled
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Phase 2 Terminated
5 enrolled
QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab
Phase 1/2 Terminated
43 enrolled 15 charts
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
Phase 2 Terminated
51 enrolled 12 charts
ULTRA-V
Phase 2/3 Terminated
277 enrolled 19 charts
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Phase 1 Terminated
21 enrolled
Ipilimumab and Local Radiation for Selected Solid Tumors
Phase 1 Terminated
3 enrolled 5 charts
ZUMA-8
Phase 1 Terminated
16 enrolled 17 charts
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
Phase 1/2 Terminated
3 enrolled 7 charts
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
Phase 1 Terminated
98 enrolled
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
Phase 2 Terminated
34 enrolled 2 charts